Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry

Journal of Biomolecular Screening

Volumn 9, Issue 6, 2004, Pages 516-524

  Bradley, Joe ^a   Gill, Jasween ^a   Bertelli, Francois ^a   Letafat, Sara ^a   Corbau, Romu ^a   Hayter, Paul ^a   Harrison, Paula ^a   Tee, Andy ^a   Keighley, Wilma ^a   Perros, Manos ^a   Ciaramella, Giuseppe ^a   Sewing, Andreas ^a   Williams, Christine ^a  

^a PFIZER INC   (United States)

Author keywords

CCR5; CD4; gp120; HIV; HTS

Indexed keywords

BETA GALACTOSIDASE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 160; REAGENT; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT; TAT (1 9); TAT (1-9);

ANIMAL CELL; ARTICLE; AUTOMATION; BINDING ASSAY; CELL ASSAY; CELL BASED FUSION ASSAY; CELL FUSION; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; ROBOTICS; ANIMAL; BINDING SITE; BIOASSAY; CELL LINE; CHO CELL; CRICETULUS; DRUG ANTAGONISM; HAMSTER; HELA CELL; INSTRUMENTATION; METABOLISM; METHODOLOGY; TIME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; ANTIGENS, CD4; BETA-GALACTOSIDASE; BINDING SITES; BIOLOGICAL ASSAY; CELL FUSION; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; GENE PRODUCTS, TAT; HELA CELLS; HIV ENVELOPE PROTEIN GP160; HIV FUSION INHIBITORS; HIV-1; HUMANS; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; ROBOTICS; TIME FACTORS; TRANSFECTION;

EID: 16644382151     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1177/1087057104264577     Document Type: Article

References (23)

1. Gillim L, Gusella GL, Vargas J Jr, Marras D, Koltman ME, Cara A: Development of a novel screen for protease inhibitors. Clin Diag Lab Immunol 2001;8(2):437-440.
2. Zhang J-H, Chen T, Nguyen SH, Oldenburg KR: A high-throughput homogeneous assay for reverse transcriptase using generic reagents and time-resolved fluorescence detection. Anal Biochem 2000;281(2):182-186.
3. Cummings RT, McGovern HM, Zheng S, Park YW, Hermes JD: Use of a phosphotyrosine-antibody pair as a general detection method in homogeneous time-resolved fluorescence: application to human immunodeficiency viral protease. Anal Biochem 1999;269(1):79-93.
4. Lorenzi P, Yerly S, Abderrakim K, Fathi M, Rutschman OT, von Overbeck J, et al: Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritanovir plus saquinavir. Swiss HIC Cohort Study. AIDS 1997;11(12):F95-99.
5. Moyle G: Clinical manifestations and management of antiretroviral nucleoside analog-related mitchondrial toxicity. Clin Ther 2000;22(8):911-936.
6. Pillay D, Taylor S, Richman DD: Incidence and impact of resistance against approved antiretroviral drugs. Rev Med Virol 2000;10(4):231-253.
7. Shafer RW: Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002;15(2):247-277.
8. Chan DC, Kim PS: HIV entry and its inhibition. Cell 1998;93:681-684.
9. Moore JP, Trkola A, Dragic T: Co-receptors for HIV-1 entry. Curr Opin Immunol 1997;9(4):549-550.
10. Xiao X, Wu L, Stantchev TS, Feng Y-R, Ugolini S, Chen H, et al: Constitutive cell surface association between CD4 and CCR5. Proc Natl Acad Sci U S A 1999;96:7496-7501.
11. Beutler JA, McMahon JB, Johnson TR, O'Keefe BR, Buzzell RA, Robbins D, et al: High-throughput screening for cyanovirin-N mimetics binding to HIV gp41. J Biomol Screening 2002;7(2):105-110.
12. McMahon JB, Beutler JA, O'Keefe BR, Goodrum CB, Myers MA, Boyd MR: Development of a cyanovirin-N/HIV-1 gp120 binding assay for high throughput screening of natural products by time-resolved fluorescence. J Biomol Screening 2000;5(3):169-176.
13. Shiraishi M, Aramaki Y, Seto M, Imoto H, Nishikawa Y, Kanzaki W, et al: Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J Med Chem 2000;43(10):2049-2063.
14. Jiang S, Zhao Q, Debnath AK: Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des 2002;8(8):563-580.
15. Jiang S, Lin K, Zhang L, Debnath AK: A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation- specific monoclonal antibody. J Virol Methods 1999;80(1):85-96.
16. Cairns JS, D'Souza MP: Chemokines and HIV-1 second receptors: the therapeutic connection. Nature Med 1998;4(5):563-568.
17. Baik SSW, Doms RW, Doranz BJ: HIV and SIV gp120 binding does not predict co-receptor function. Virology 1999;259(2):267-273.
18. Chiba H, Asanuma S, Okamoto M, Inokoshi J, Tanaka H: A simple screening system for anti-HIV drugs: syncytium formation assay using T-cell line tropic and macrophage tropic HIV env expressing cell lines-establishment and validation. J Antibiotics 2001;54(10):818-826.
19. Hong YL, Wu LH, Cui M, McMaster G, Hunt SW, Chung F-Z: New reporter cell lines to study macrophage-tropic HIV envelope protein-mediated cell-cell fusion. AIDS Res Hum Retrovirus 1999;15(18):1667-1672.
20. Pine PS, Weaver JL, Oravecz, Pall M, Ussery M, Aszalos A: A semi-automated fluorescence based cell-to-cell fusion assay for gp120-gp41 and CD4 expressing cells. Exp Cell Res 1998;240(1):49-57.
21. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, et al: Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A 2002;99(25):16249-16254.
22. Falconer M, Smith F, Surah-Narwal S, Congrave G, Liu Z, Hayter P, et al: High-throughput screening for ion channel modulators. J Biomol Screening 2002;7(5):460-465.
23. Wright PA, Boyd HF, Bethell RC, Busch M, Gribbon P, Kraemer J, et al: Development of a 1 μl scale assay for mitogen-activated kinase kinase 7 using 2D-fluorescence intensity distribution analysis anisotropy. J Biomol Screening 2002;7(5):419-428.